Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems

被引:267
作者
Boyd, BJ
Whittaker, DV
Khoo, SM
Davey, G
机构
[1] Monash Univ, Victorian Coll Pharm, Dept Pharmaceut, Parkville, Vic 3052, Australia
[2] MaynePharma, Injectable Prod Dev, Mulgrave, Vic 3170, Australia
[3] Imaginot, Woolloongabba, Qld 4102, Australia
关键词
parenteral depot formulations; cubic phase; hexagonal phase; glycerate surfactant; in vitro release;
D O I
10.1016/j.ijpharm.2005.11.033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A new class of surfactants with glycerate headgroups, that form viscous lyotropic liquid crystalline phases in excess water, have been investigated for their potential to provide sustained release matrices for depot drug delivery. Oleyl glycerate and phytanyl glycerate were used as representative surfactants of this new class, and their behaviour compared with that of glyceryl monooleate (GMO). The surfactants were found to form reverse hexagonal phase (H-Iota Iota) in excess water, and the matrices were loaded with a series of model hydrophobic and hydrophilic drugs, (paclitaxel, irinotecan, glucose, histidine and octreotide), and the release kinetics determined. In all cases, the release behaviour obeyed Higuchi kinetics, with linear drug release versus square root of time. The H-Iota Iota phases released model drugs slower than the GMO cubic phase matrix. The oleyl glycerate matrix was found to consistently release drug faster than the phytanyl glycerate matrix, despite both matrices being based on H-Iota Iota phase. To further demonstrate the potential utility of these materials as drug depot delivery systems, an injectable precursor formulation for octreotide was also prepared and demonstrated to provide controlled release for the peptide. The stability of the H-Iota Iota phase to likely in vivo breakdown products was also assessed. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:218 / 226
页数:9
相关论文
共 23 条
[1]  
Appel Leah, 1994, Pharmaceutical Research (New York), V11, pS217
[2]  
ASHERMAN J, 1998, J CONTROL RELEASE, V25, P503
[3]   Phase behavior of the phytantriol/water system [J].
Barauskas, J ;
Landh, T .
LANGMUIR, 2003, 19 (23) :9562-9565
[4]  
Boyd B. J., 2005, International patent, Patent No. [WO2005021046, 2005021046]
[5]   Phase inversion dynamics of PLGA solutions related to drug delivery - Part II. The role of solution thermodynamics and bath-side mass transfer [J].
Brodbeck, KJ ;
DesNoyer, JR ;
McHugh, AJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (03) :333-344
[6]   Low viscosity monoglyceride-based drug delivery systems transforming into a highly viscous cubic phase [J].
Chang, CM ;
Bodmeier, R .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 173 (1-2) :51-60
[7]   Phase behavior of a monoacylglycerol (Myverol 18-99K)/water system [J].
Clogston, J ;
Rathman, J ;
Tomasko, D ;
Walker, H ;
Caffrey, M .
CHEMISTRY AND PHYSICS OF LIPIDS, 2000, 107 (02) :191-220
[8]   Surfactant self-assembly objects as novel drug delivery vehicles [J].
Drummond, CJ ;
Fong, C .
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 1999, 4 (06) :449-456
[9]  
ERICSSON B, 1991, ACS SYM SER, V469, P251
[10]  
FEUER J, 2003, CUBOSOME TECHNOLOGY